Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Idiopathic Pulmonary Fibrosis Clinical Trial Report Overview
A total of 713 idiopathic pulmonary fibrosis clinical trials were conducted as of January 2024. The Idiopathic Pulmonary Fibrosis clinical trial report provides a comprehensive understanding of the idiopathic pulmonary fibrosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · The US
· China · The UK · Australia · Japan · Germany · Canada · Italy · France · South Korea |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · F. Hoffmann-La Roche Ltd
· C. H. Boehringer Sohn AG & Co KG · Bristol-Myers Squibb Co · Galapagos NV · Johnson & Johnson · Laboratory Corp of America Holdings · ICON Plc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Idiopathic Pulmonary Fibrosis Clinical Trials Segmentation by Regions and Countries
As of January 2024, Asia-Pacific led the idiopathic pulmonary fibrosis clinical trials landscape with more than 35% of the clinical trials conducted there
The key regions considered for idiopathic pulmonary fibrosis clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of idiopathic pulmonary fibrosis clinical trials as of January 2024. France had the highest average patient enrollment in idiopathic pulmonary fibrosis clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan had the highest proportion of Idiopathic Pulmonary Fibrosis to Respiratory clinical trials as of January 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico had the highest proportion of Idiopathic Pulmonary Fibrosis to Respiratory clinical trials as of January 2024.
Idiopathic Pulmonary Fibrosis Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Idiopathic Pulmonary Fibrosis Clinical Trials
Idiopathic Pulmonary Fibrosis Clinical Trials Segmentation by Sponsor Types
The key sponsor types for idiopathic pulmonary fibrosis clinical trials are company, institution, and the government. As of January 2024, more than 69% of idiopathic pulmonary fibrosis clinical trials conducted were sponsored by company sponsor type, followed by institution.
Idiopathic Pulmonary Fibrosis Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Idiopathic Pulmonary Fibrosis Clinical Trials
Idiopathic Pulmonary Fibrosis Clinical Trials - Competitive Landscape
In 2024, F. Hoffmann-La Roche Ltd conducted the highest number of idiopathic pulmonary fibrosis clinical trials
A few of the leading sponsors for idiopathic pulmonary fibrosis clinical trials are:
- Hoffmann-La Roche Ltd
- H. Boehringer Sohn AG & Co KG
- Bristol-Myers Squibb Co
- Galapagos NV
- Johnson & Johnson
- Laboratory Corp of America Holdings
- ICON Plc
Idiopathic Pulmonary Fibrosis Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Idiopathic Pulmonary Fibrosis Clinical Trials
Segments Covered in the Report
Idiopathic Pulmonary Fibrosis Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Idiopathic Pulmonary Fibrosis Clinical Trials Country Outlook (2024)
- The US
- China
- The UK
- Australia
- Japan
- Germany
- Canada
- Italy
- France
- South Korea
Idiopathic Pulmonary Fibrosis Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
C. H. Boehringer Sohn AG & Co KG
Bristol-Myers Squibb Co
Galapagos NV
Johnson & Johnson
Laboratory Corp of America Holdings
ICON Plc
Nucleus Network Ltd
Vicore Pharma Holding AB
Pliant Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of idiopathic pulmonary fibrosis clinical trials in January 2024?
Asia-Pacific accounted for the highest number of idiopathic pulmonary fibrosis clinical trials as of January 2024.
-
Which country conducted the highest number of idiopathic pulmonary fibrosis clinical trials in January 2024?
The US conducted the highest number of idiopathic pulmonary fibrosis clinical trials as of January 2024.
-
Which sponsor type was the most prominent in the idiopathic pulmonary fibrosis clinical trials in January 2024?
As of January 2024, most of the idiopathic pulmonary fibrosis clinical trials conducted were sponsored by company sponsor type.
-
Which are the leading sponsors of idiopathic pulmonary fibrosis clinical trials?
A few of the leading sponsors of idiopathic pulmonary fibrosis clinical trials are F. Hoffmann-La Roche Ltd, C. H. Boehringer Sohn AG & Co KG, Bristol-Myers Squibb Co, Galapagos NV, Johnson & Johnson, Laboratory Corp of America Holdings, and ICON Plc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.